Risk factor
Good trading liquidity
Profitability factor
Overvalued vs peers
About
Betta Pharmaceuticals Co., Ltd. researches and develops, manufactures, and markets medicines for the treatment of cancer in China. The company offers Icotinib hydrochloride, an oral epidermal growth factor receptor tyrosine kinase inhibitor, which is used to treat non-small-cell lung cancer; and Ensartinib hydrochloride, an anaplastic lymphoma kinase inhibitor for the treatment of non-small cell lung cancer. Betta Pharmaceuticals Co., Ltd. was founded in 2003 and is headquartered in Hangzhou, China.
Company Valuation
From both historical and forecast perspectives, the stock is overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, overvalued on EV/EBIT
Target Price
The average target price of 300558.SZ is 64 and suggests 40% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to inc
Buy
Sell